Related Experiment Video
Updated: Jun 10, 2026
Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
LUMINEX technology detects plasma inflammatory factor expression levels in children with severe and non-severe
Qichao Yang1, Jun Xie1, Hunian Li2
1Department of Emergency Medicine, Shiyan Renmin Hospital (Affiliated People's Hospital of Hubei University of Medicine), No.39 Chaoyang Middle Road, Maojian District, Shiyan City, Hubei Province, 442000, China.
Insights
LUMINEX technology effectively detects inflammatory markers like IL-1β, TNF-α, and IL-10 in pediatric community-acquired pneumonia (CAP), aiding in disease severity assessment and prognosis prediction.
Area of Science:
- Pediatric Infectious Diseases
- Immunology
- Biomarker Discovery
Background:
- Community-acquired pneumonia (CAP) in children presents a significant clinical challenge, with severity assessment and prognosis prediction requiring accurate diagnostic tools.
- Inflammatory mediators, including interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and interleukin-10 (IL-10), play crucial roles in the pathogenesis and clinical course of CAP.
Purpose of the Study:
- To evaluate the clinical utility of LUMINEX technology for quantifying plasma inflammatory factors (IL-1β, TNF-α, IL-10) in pediatric CAP.
- To compare LUMINEX performance against traditional ELISA methods for assessing disease severity and predicting prognosis in children with CAP.
Main Methods:
- A cohort of 72 pediatric CAP patients (28 severe, 44 non-severe) and 80 healthy controls were analyzed.
- Plasma and serum samples were tested for IL-1β, TNF-α, and IL-10 concentrations using LUMINEX multiplex analysis and ELISA.
- Comparative analyses assessed inflammatory marker expression across severity groups and their diagnostic and prognostic predictive values.
Main Results:
- Significantly elevated IL-1β, TNF-α, and IL-10 levels were observed in severe CAP cases compared to non-severe cases and controls (P < 0.05).
- LUMINEX and ELISA demonstrated comparable diagnostic accuracy for identifying severe pneumonia.
- Increased inflammatory marker levels correlated with unfavorable clinical outcomes, with TNF-α and IL-10 showing superior prognostic predictive performance (higher AUC).
Conclusions:
- LUMINEX technology provides a valuable tool for detecting plasma inflammatory cytokines in pediatric CAP, aiding in condition assessment.
- This method demonstrates clinical utility in evaluating prognosis, supporting its promotion for wider application in pediatric respiratory infections.
Objective:
This study aimed to evaluate the clinical utility of LUMINEX technology in detecting plasma inflammatory factor expression levels (IL-1β, TNF-α, and IL-10) in children with severe and non-severe community-acquired pneumonia (CAP), comparing its performance with traditional ELISA methods for disease severity assessment and prognosis prediction.
Methods:
This study enrolled 72 pediatric patients diagnosed with community-acquired pneumonia at our institution between January 2023 and December 2024, comprising 28 severe cases and 44 non-severe cases, along with 80 age-matched healthy controls. Inflammatory marker concentrations [interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10)] were quantified in plasma and serum samples using LUMINEX multiplex analysis and ELISA techniques. Comparative analyses examined inflammatory mediator expression patterns across disease severity groups and evaluated their diagnostic discrimination capacity, while prognostic assessments investigated the predictive value of plasma inflammatory markers.
Results:
Comparative analysis revealed significantly elevated concentrations of IL-1β, TNF-α, and IL-10 in both plasma and serum samples from severe cases compared to non-severe patients (P < 0.05), with non-severe patients also showing higher levels than healthy controls (P < 0.05). Both LUMINEX-based plasma analysis and ELISA serum measurements demonstrated comparable diagnostic accuracy for severe pneumonia identification. Prognostic evaluation indicated that patients with unfavorable outcomes exhibited increased plasma inflammatory marker levels relative to those with favorable prognoses (P < 0.05). ROC analysis showed superior predictive performance for TNF-α and IL-10 (higher AUC values) compared to IL-1β in forecasting clinical outcomes.
Conclusion:
The detection of plasma inflammatory cytokines in children with community-acquired pneumonia by LUMINEX technology is helpful to determine the condition and evaluate the prognosis of children, and it is worth promoting.
